Correction to “Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06)”

IF 6.1 2区医学 Q1 ONCOLOGY

Cancer Pub Date : 2025-03-08 DOI:10.1002/cncr.35777

引用次数: 0

Abstract

Kim M, Kim YJ, Suh KJ, et al. Phase 2 trial of avelumab in combination with gemcitabine in advanced leiomyosarcoma as a second-line treatment (EAGLES, Korean Cancer Study Group UN18-06). Cancer. 2025;131(1):e35609. doi:10.1002/cncr.35609

In the original title of the article, the Korean Cancer Study Group clinical trial number was incorrectly listed as “UN18-09.” The correct clinical trial number is “UN1806.”

The authors apologize for this error.

查看原文本刊更多论文

求助全文

约1分钟内获得全文求助全文

来源期刊

Cancer 医学-肿瘤学

CiteScore

13.10

自引率

3.20%

发文量

480

审稿时长

2-3 weeks

期刊介绍： The CANCER site is a full-text, electronic implementation of CANCER, an Interdisciplinary International Journal of the American Cancer Society, and CANCER CYTOPATHOLOGY, a Journal of the American Cancer Society. CANCER publishes interdisciplinary oncologic information according to, but not limited to, the following disease sites and disciplines: blood/bone marrow; breast disease; endocrine disorders; epidemiology; gastrointestinal tract; genitourinary disease; gynecologic oncology; head and neck disease; hepatobiliary tract; integrated medicine; lung disease; medical oncology; neuro-oncology; pathology radiation oncology; translational research